Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications

被引:26
作者
Qin, Jinling [2 ,3 ]
Cheng, Weyland [1 ]
Duan, Yong-Tao [1 ]
Yang, Hua [2 ,3 ]
Yao, Yongfang [1 ,2 ,3 ]
机构
[1] Zhengzhou Univ, Henan Prov Key Lab Childrens Genet & Metab Dis, Childrens Hosp, Zhengzhou 450018, Henan, Peoples R China
[2] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[3] Zhengzhou Univ, Minist Educ China, Key Lab Adv Drug Preparat Technol, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Heterocyclic compound; indazole; therapeutic application; structure-activity relationship; pharmacology; activity;
D O I
10.2174/1871520620999200818160350
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Heterocyclic compounds, also called heterocycles, are a major class of organic chemical compound that plays a vital role in the metabolism of all living cells. The heterocyclic compound, indazole, has attracted more attention in recent years and is widely present in numerous commercially available drugs. Indazole-containing derivatives, representing one of the most important heterocycles in drug molecules, are endowed with a broad range of biological properties. Methods: A literature search was conducted in PubMed, Google Scholar and Web of Science regarding articles related to indazole and its therapeutic application. Results: The mechanism and structure-activity relationship of indazole and its derivatives were described. Based on their versatile biological activities, the compounds were divided into six groups: anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour. At least 43 indazole-based therapeutic agents were found to be used in clinical application or clinical trials. Conclusion: This review is a guide for pharmacologists who are in search of valid preclinical/clinical drug compounds where the progress of approved marketed drugs containing indazole scaffold is examined from 1966 to the present day. Future direction involves more diverse bioactive moieties with indazole scaffold and greater insights into its mechanism.
引用
收藏
页码:839 / 860
页数:22
相关论文
共 189 条
  • [1] Acar Yahya Ayhan, 2014, Case Rep Psychiatry, V2014, P290365, DOI 10.1155/2014/290365
  • [2] PHASE-I/II TRIAL OF GRANISETRON - A NOVEL 5-HYDROXYTRYPTAMINE ANTAGONIST FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
    ADDELMAN, M
    ERLICHMAN, C
    FINE, S
    WARR, D
    MURRAY, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (02) : 337 - 341
  • [3] Ali NAS, 2013, MINI-REV MED CHEM, V13, P1792
  • [4] ALLEN A, 1994, EUR J CLIN PHARMACOL, V46, P159
  • [5] An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
    Andorsky, David J.
    Kolibaba, Kathryn S.
    Assouline, Sarit
    Forero-Torres, Andres
    Jones, Vicky
    Klein, Leonard M.
    Patel-Donnelly, Dipti
    Smith, Mitchell
    Ye, Wei
    Shi, Wen
    Yasenchak, Christopher A.
    Sharman, Jeff P.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (02) : 215 - 222
  • [6] Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
    Ardini, Elena
    Menichincheri, Maria
    Banfi, Patrizia
    Bosotti, Roberta
    De Ponti, Cristina
    Pulci, Romana
    Ballinari, Dario
    Ciomei, Marina
    Texido, Gemma
    Degrassi, Anna
    Avanzi, Nilla
    Amboldi, Nadia
    Saccardo, Maria Beatrice
    Casero, Daniele
    Orsini, Paolo
    Bandiera, Tiziano
    Mologni, Luca
    Anderson, David
    Wei, Ge
    Harris, Jason
    Vernier, Jean-Michel
    Li, Gang
    Felder, Eduard
    Donati, Daniele
    Isacchi, Antonella
    Pesenti, Enrico
    Magnaghi, Paola
    Galvani, Arturo
    [J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (04) : 628 - 639
  • [7] Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study
    Awan, Farrukh T.
    Thirman, Michael J.
    Patel-Donnelly, Dipti
    Assouline, Sarit
    Rao, Arati, V
    Ye, Wei
    Hill, Brian
    Sharman, Jeff P.
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 1972 - 1977
  • [8] Advance of 2-methoxyestradiol as a promising anticancer agent for cancer therapy
    Ba, Mengyu
    Duan, Yongtao
    [J]. FUTURE MEDICINAL CHEMISTRY, 2020, 12 (04) : 273 - 275
  • [9] Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia
    Bachegowda, Lohith
    Morrone, Kerry
    Winski, Shannon L.
    Mantzaris, Ioannis
    Bartenstein, Matthias
    Ramachandra, Nandini
    Giricz, Orsi
    Sukrithan, Vineeth
    Nwankwo, George
    Shahnaz, Samira
    Bhagat, Tushar D.
    Bhattacharyya, Sanchari
    Assal, Amer
    Shastri, Aditi
    Gordon-Mitchell, Shanisha
    Pellagatti, Andrea
    Boultwood, Jacqueline
    Schinke, Carolina
    Yu, Yiting
    Guha, Chandan
    Rizzi, James
    Garrus, Jennifer
    Brown, Suzy
    Wollenberg, Lance
    Hogeland, Grant
    Wright, Dale
    Munson, Mark
    Rodriguez, Mareli
    Gross, Stefan
    Chantry, David
    Zou, Yiyu
    Platanias, Leonidas C.
    Burgess, Laurence E.
    Pradhan, Kith
    Steidl, Ulrich
    Verma, Amit
    [J]. CANCER RESEARCH, 2016, 76 (16) : 4841 - 4849
  • [10] Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma
    Barat, Samarpita
    Bozko, Przemyslaw
    Chen, Xi
    Scholta, Tim
    Hanert, Franziska
    Goetze, Julian
    Malek, Nisar P.
    Wilkens, Ludwig
    Plentz, Ruben R.
    [J]. MOLECULAR CARCINOGENESIS, 2016, 55 (12) : 2037 - 2050